Posts by Mourabit Halima

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.

A recent study published in JNCI Cancer Spectrum (Jan 2025) introduces a machine learning-based cancer-specific cardiovascular disease (CVD) risk score, designed to improve risk prediction for breast, colorectal, and lung…

From July 5th to 7th, the "2024 Annual Progress Seminar in Clinical Oncology in China (BOC)," hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO. Additionally, it focused on the theme of the 2024 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," and discussed and interpreted major research presented at ASCO. To gain in-depth insights into the relevant content and trends, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Donglu Zhao from the Harbin Institute of Hematology and Oncology, who provided an excellent analysis of these topics.

From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the contributors to the "Annual Advances in Clinical Oncology Research in China," Professor Biyun Wang from Fudan University Shanghai Cancer Center also detailed the ACE-Breast-02 study at this conference, showcasing the rigor and innovation of Chinese research. "Oncology Frontier" interviewed Professor Biyun Wang, and the compilation is presented below.

Dr. Hans Wildiers and colleagues published findings from the AIPAC Phase IIb trial (Clin Cancer Res, Feb 2024), evaluating eftilagimod alpha (efti), a soluble LAG-3 protein, in combination with paclitaxel…

With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People's Liberation Army General Hospital shared insights on the committee members' demeanor, the crucial role of young doctors within the association, and experiences and advice for young doctors on their growth path. Drawing from his own experiences, Professor Jiang encouraged young doctors to seize opportunities, actively engage in clinical practice and research, and contribute to both personal and societal value. He also offered words of encouragement to students aspiring to enter the medical field, urging them to pursue their dreams and contribute to the advancement of medical science in China.